Iomeprol

Last updated

Iomeprol
Iomeprol-Structural Formula V.1.svg
Clinical data
Trade names Iomervu, others
License data
Routes of
administration
Intravenous, intra-arterial
ATC code
Legal status
Legal status
Pharmacokinetic data
Metabolism none
Elimination half-life 109±20 min
Excretion Kidney
Identifiers
  • 1-N,3-N-bis(2,3-dihydroxypropyl)-5-(2-hydroxy-N-methylacetamido)-2,4,6-triiodobenzene-1,3-dicarboxamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
CompTox Dashboard (EPA)
Chemical and physical data
Formula C17H22I3N3O8
Molar mass 777.089 g·mol−1
3D model (JSmol)
  • Ic1c(c(I)c(c(I)c1N(C(=O)CO)C)C(=O)NCC(O)CO)C(=O)NCC(O)CO
  • InChI=1S/C17H22I3N3O8/c1-23(9(29)6-26)15-13(19)10(16(30)21-2-7(27)4-24)12(18)11(14(15)20)17(31)22-3-8(28)5-25/h7-8,24-28H,2-6H2,1H3,(H,21,30)(H,22,31)
  • Key:NJKDOADNQSYQEV-UHFFFAOYSA-N

Iomeprol, sold under the brand name Imeron among others, is a medication used as a radiocontrast agent in X-ray imaging. [1] [2] [3]

Contents

Iomeprol was approved for medical use in the United States in November 2024. [1] [4] [5]

Side effects

It is classified as a water-soluble, nephrotrophic, low osmolar X-ray contrast medium. [2] Low osmolar non-ionic agents are better tolerated and less likely to cause side effects than the high osmolar ionic agents. [2]

Society and culture

Iomeprol is not metabolized in the human body but excreted in unchanged form.[ medical citation needed ] It is decomposed slowly and can therefore accumulate in the environment. [6]

Iomeprol was approved for medical use in the United States in November 2024. [1] [4]

Brand names

Iomeprol is sold under the brand name Iomervu. [1]

References

  1. 1 2 3 4 5 fda.gov
  2. 1 2 3 Rossiter D (2014). South African medicines formulary (11th ed.). Rondebosch, South Africa: Health and Medical Pub. Group .of the South African Medical Association. ISBN   978-1-875098-30-9. OCLC   869772940.
  3. Haberfeld H, ed. (2020). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Iomeron 300 mg J/ml-Infusionsflasche.
  4. 1 2 "Novel Drug Approvals for 2024". U.S. Food and Drug Administration (FDA). 1 October 2024. Retrieved 29 November 2024.
  5. New Drug Therapy Approvals 2024 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2025. Archived from the original on 21 January 2025. Retrieved 21 January 2025.
  6. Pfundstein P, Martin C, Schulz W, Seitz W, Ruth KM, Wille A, et al. (January 2015). "IC-ICP/MS-Analytik". GIT Labor-Fachzeitschrift (in German): 29–31.